Department of Defense explores AI-enabled infection control

The technology examines vital signs and other biomarkers to predict the likelihood of infection


The technology, developed in part by the U.S. Department of Defense (DoD), examines vital signs and other biomarkers to predict the likelihood of infection up to 48 hours ahead of clinical suspicion, according to an article on the Healthcare IT News website.

The technology is intended for U.S. service members but expected to be used widely by civilians. 

The healthcare technology company, Royal Philips, and the DoD collaborated on the 18-month project.

The technology is expected to be broadly applicable to civilian healthcare settings. It will eventually be used in scenarios where vital signs and biomarkers fluctuate, like during physical exertion and heat stress.

Read the article.



October 29, 2019


Topic Area: Infection Control


Recent Posts

Probiotic Cleaners: The Start of a Cleaning Revolution?

Advantages of probiotic cleaning include fewer resistant genes and cost savings through decreased antibiotic use.


Gun Incident Highlights Need for Security Infrastructure

A man was arrested at Aultman Memorial Hospital after allegedly firing a gun in the ER.


Creative Solutions in Healthcare Acquires 5 Skilled Nursing Facilities

Each location is planned to begin substantial upgrades to infrastructure and resident services.


Over 700 Hospitals at Risk of Closure

Hospitals are citing financial problems at the main cause of potential closure.


Astrana Health Fully Acquires Prospect Health

They completed the acquisition of Prospect Health for a total purchase price of $708 million.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.